Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 284

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth

Open access
Roovers, Rob C., Vosjan, Maria J.W.D., Laeremans, Toon, el Khoulati, Rachid, de Bruin, Renée C.G., Ferguson, Kathryn M., Verkleij, Arie J., van Dongen, Guus A.M.S., van Bergen en Henegouwen, Paul M.P. · 2011 · International Journal of Cancer

Abstract

The epidermal growth factor receptor (EGFR) has been shown to be a valid cancer target for antibody‐based therapy. At present, several anti‐EGFR monoclonal antibodies have been successfully used, such as cetuximab and matuzumab. X‐ray crystallography data show that these antibodies bind to different epitopes on the ecto‐domain of EGFR, providing a rationale for the combined use of these two antibody specificities. We have previously reported on the successful isolation of antagonistic anti‐EGFR nanobodies. In our study, we aimed to improve the efficacy of these molecules by combining nanobodies with specificities similar to both cetuximab and matuzumab into a single biparatopic molecule. Carefully designed phage nanobody selections resulted in two sets of nanobodies that specifically blocked the binding of either matuzumab or cetuximab to EGFR and that did not compete for each others' binding. A combination of nanobodies from both epitope groups into the biparatopic nanobody CONAN‐1 was shown to block EGFR activation more efficiently than monovalent or bivalent (monospecific) nanobodies. In addition, this biparatopic nanobody potently inhibited EGF‐dependent cell proliferation. Importantly, in an in vivo model of athymic mice bearing A431 xenografts, CONAN‐1 inhibited tumour outgrowth with an almost similar potency as the whole mAb cetuximab, despite the fact that CONAN‐1 is devoid of an Fc portion that could mediate immune effector functions. Compared to therapy using bivalent, monospecific nanobodies, CONAN‐1 was clearly more potent in tumour growth inhibition. These results show that the rational design of biparatopic nanobody‐based anticancer therapeutics may yield potent lead molecules for further development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.26145

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

Metadata

Authors
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2011-08-08
Volume
129
Issue
8
Pages
2013-2024
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2088080828
Cited by
284
References
41
FWCI
9.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.